Monopar Therapeutics Inc..
MNPR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics primarily for the treatment of cancer. Their pipeline includes Validirex, an anti-cancer antibody, and camsirubicin, a Phase 2-ready topoisomerase II inhibitor. The company is dedic...Show More
Better Health for All
-10
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious conditions like cancer and Wilson disease. Their entire business is devoted to health improvement, with products like ALXN1840 showing sustained clinical benefits and exceptional efficacy in trials for Wilson disease.
1
The company has no revenue from products with negative health outcomes. Research and development expenses increased to $1,643,000 in Q1 2025 from $966,000 in Q1 2024.
2
The company includes forward-looking statements in its announcements, acknowledging risks related to adverse effects, trial outcomes, regulatory processes, and market acceptance.
3
The company also mentions the risk of unexpected serious adverse effects or lack of efficacy in humans for its MNPR-101 program and the potential for clinical holds due to adverse events.
4
For clinical trials, the company has an Expanded Access Program (EAP) for patients with serious or life-threatening conditions with no comparable treatment, and eligibility criteria are available on clinicaltrials.gov.
5
Fair Money & Economic Opportunity
0
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer.
1
The provided articles detail its public offering, clinical trials, FDA approvals for expanded access programs, and inclusion in stock indexes. There is no evidence that the company offers lending, insurance, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity are not applicable to its core business operations.
Fair Pay & Worker Respect
0
Monopar Therapeutics Inc. has 10 full-time employees as of 2023.
1
Due to this small workforce headcount, turnover metrics are considered not meaningful, aligning with a score of 0 for turnover rate. There are no reported regulatory actions, violations, fines, or compliance issues across the provided articles, indicating no public record of labor-law breaches, which maps to a score of 0 for labor violation incidents.
2
No specific, concrete data points were provided for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, insecure contract share, or health insurance coverage.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Monopar Therapeutics Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided Audit Committee Charter outlines the committee's responsibilities for financial statements, internal controls, compliance, and independent auditor oversight.
1
However, it does not contain any specific quantitative data, regulatory actions, certifications, awards, or comparisons to industry benchmarks required to score the KPIs for Honest & Fair Business.
2
Kind to Animals
-20
Monopar Therapeutics conducts animal studies as part of its research and development, including preclinical testing.
1
The company explicitly states that these animal studies are required by the FDA and adheres to Good Laboratory Practices (GLP) for them.
2
There is no evidence of a policy prohibiting discretionary animal testing, but the company's statements emphasize compliance with legal mandates for animal studies.
3
No War, No Weapons
0
No specific evidence was found in the provided articles regarding Monopar Therapeutics Inc.'s involvement in arms manufacturing, military contracts, or conflict facilitation. The articles discuss general US military spending or a pharmaceutical licensing agreement for the company, without providing any data points relevant to the 'No War, No Weapons' ethical value for Monopar Therapeutics Inc.
1
Planet-Friendly Business
0
No specific, concrete data points were found in the provided articles to assess Monopar Therapeutics Inc. against any of the Planet-Friendly Business KPIs. The articles indicate that relevant environmental metrics are 'Not mentioned' or 'missing'.
1
Respect for Cultures & Communities
0
No evidence available to assess Monopar Therapeutics Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company has reported no data breaches or incidents that resulted in a material adverse impact to the business.
1
Employee training on phishing emails and internal controls is conducted.
2
Internal controls are in place to mitigate fraudulent invoice payments.
3
The company also utilizes an internal server firewall and performs daily malware scans.
4
Zero Waste & Sustainable Products
0
The provided article for Monopar Therapeutics Inc. does not contain any specific data points or information relevant to the 'Zero Waste & Sustainable Products' ethical value.
1
No metrics on waste management, product recyclability, packaging sustainability, or other related initiatives are available in the evidence.
2